Last reviewed · How we verify
NCT06675591: RASC-HypoNa
Mortality and Neurologic Outcomes in Rapid vs. Slow Hyponatremia Correction
trial testing Rapid sodium correction in Hyponatremia in 2,037 participants. Completed in 1 May 2024.
30 April 2024
Quick facts
| Lead sponsor | Hospital Italiano de Buenos Aires |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 2,037 |
| Start date | 1 March 2024 |
| Primary completion | 30 April 2024 |
| Estimated completion | 1 May 2024 |
| Sites | 1 location across Argentina |
Drugs / interventions tested
- Rapid sodium correction
- Slow sodium correction
Conditions studied
- Hyponatremia — all drugs for Hyponatremia →
- Hospitalisation — all drugs for Hospitalisation →
- Mortality — all drugs for Mortality →
- SEVERE HYPONATREMIA — all drugs for SEVERE HYPONATREMIA →
Sponsor
Hospital Italiano de Buenos Aires
Who can join
18 and older, any sex, with Hyponatremia or Hospitalisation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study examines the impact of different rates of sodium correction on the outcomes of patients with severe hyponatremia (serum sodium ≤ 120 mEq/L). Hyponatremia is a condition where blood sodium levels are dangerously low, and its treatment must be carefully managed to avoid complications. Standard guidelines recommend correcting sodium levels slowly to prevent a rare but serious neurological condition called osmotic demyelination syndrome (ODS). However, recent evidence suggests that a faster rate of sodium correction may reduce hospital stay length and mortality without increasing the risk of ODS. This retrospective study, conducted from 2010 to 2023 at a hospital in Buenos Aires, Argentina. It compares the outcomes of patients who had their sodium levels corrected rapidly (≥ 8 mEq/L in 24 hours) to those who had slower corrections. The primary outcomes measured are mortality and the development of ODS.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06675591
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hyponatremia
Currently open trials in the same condition.
- NCT07273630 — Effect of Protein Supplementation and Fluid Restriction on Plasma Sodium Levels in Patients Undergoing Pituitary Surgery · NA · recruiting
- NCT06020495 — Systematic Use of DDAVP to Prevent Serum Sodium Overcorrection in Severe Hyponatremia · Phase 3 · recruiting
- NCT06781710 — Analysis of the Epidemiology, Clinical Presentation and Therapy as Well as Therapy-associated Risk of Demyelination Synd · recruiting
- NCT07430787 — Hyponatremia - Complications, Prognosis, Epidemiology in Finnish Tertiary Care · active not recruiting
- NCT06408077 — Regulation of Extracellular Sodium in End Stage Renal Disease Upon Volume and Electrolyte Challenges · NA · recruiting
Other Hospital Italiano de Buenos Aires trials
Trials by the same sponsor.
- NCT07397416 — Impact of Implementing a Rapid PCR-based Algorithm for Carbapenemase-producing Enterobacterales (CPE) and Infection Cont · NA · not yet recruiting
- NCT07167173 — Predictive Model for Multidrug Resistance in Patients Admitted to the Emergency Department With Sepsis · not yet recruiting
- NCT06683781 — Ventilatory Settings and Monitoring Variables Associated With Weaning Failure in Critically Ill Patients · recruiting
- NCT06573723 — Institutional Registry of Rare Diseases · recruiting
- NCT06609798 — Ultrasound Assessment During Weaning from Mechanical Ventilation · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06675591 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hospital Italiano de Buenos Aires
- Last refreshed: 5 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06675591.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing